Thermal Cures in the Treatment of Multiple Sclerosis

Association Francaise pour la Recherche Thermale200 enrolled

Overview

Multiple Sclerosis (MS) is a chronic, progressive disease with a high prevalence in France, with significant public health consequences. The benefit of spa treatments on the quality of life in this population has not been evaluated. The methods of study in clinical pharmacology can be a scientific methodological model for the evaluation of thermal practices and it is in this perspective that investigators want to lead this project.

Multiple sclerosis (MS) is a chronic, progressive disease with a high prevalence in France, and its consequences in terms of public health are important. In this disease, the alteration of the quality of life (QoL) is constant and multifactorial : pain, fatigue, decrease in functional capacities, sleep disorders, cognitive disorders, vesico-sphincterian disorders, anomolytic disorders. -rectal and genito-sexual. The benefit of thermal cures on the quality of life in this population has not been evaluated, even if there is some literature in the literature suggesting a benefit of hydrotherapy on equilibrium or on pain.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

200

Conditions

Multiple Sclerosis

Interventions

Spa therapyOTHER

The standardized treatment will consist of 4 spa treatments per day for 3 consecutive weeks. Each day, the patient receives at least four treatments, among which: * Cure of Drink (in addition to 4 daily cares) * Bath in running water: Bath * Bath in running water: Pool at 32 ° C * Bath with aerobain * Immersion shower bath * Shower of high pressure under immersion in swimming pool * General penetrating shower * General jet shower * Local jet shower * Local mud bath at the feet * Single poultice * Multiple poultice * Compress * Mobilization pool * Massages under water

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient with primary or progressive secondary-phase MS * Showing EDSS \<7 severity criteria * Patient with MS for whom an indication of spa treatment has been made, * Patient agreeing to participate in this study and therefore accepting the constraints related to the design "immediate cure-deferred cure", * Patient receiving the general social security scheme, * Patient having given written consent to participate in the study Exclusion Criteria: * Patient does not meet the inclusion criteria, * Patient with relapsing remitting MS * Patient unfit according to the investigator to complete the rating scales * Patient with heat intolerance called "Uhthoff effect" * Patient with a contraindication to the spa treatment: urinary or faecal leakage, wound, thrombophlebitis less than three months old, unstabilized cardio respiratory disease. * Patient with serious life-threatening condition (ie, cancer) * Patient under tutorship or curatorship * Patient participating in another interventional clinical research project

Locations (1)

Département de Médecine Physique et de Réadaptation, Hopital LAPEYRONIE

Montpellier, France

RECRUITING

Outcomes

Primary Outcomes

Benefit of spa treatment on quality of life assessed by the scale SEP-59

Difference of the score of quality of live assessed by the scale SEP-59 between the patient will receive the immediat spa therapy and the second group which won't receive the spa therapy immediately. SEP-59 is built on the basis of a generic scale, the SF-36. The analysis of SEP-59 is done by computer processing in order to calculate the score of the various axes (pain, physical activity, general wellbeing ...) which are independent (there is no overall score).

Time frame: within 15 weeks after inclusion

Secondary Outcomes

Benefit of a spa treatment based on average number of steps per day for one week assessed by actimeter

Difference of the average number of steps per day for one week between the patient will receive the immediat spa therapy and the second group which won't receive the spa therapy immediately.

Time frame: 9 weeks after inclusion

Benefit of a thermal cure based on treatment consumption of hospital and ambulatory care

Difference of the number of treatment consumption of hospital and ambulatory care between the patient will receive the immediat spa therapy and the second group which won't receive the spa therapy immediately

Time frame: 15 to 17 weeks after inclusion

Benefit of a thermal cure based on depression and anxiety assessed by the scale Hospital Anxiety and depression scale

Difference of the level of pain assessed by the scale Hospital Anxiety and depression between the patient will receive the immediat spa therapy and the second group which won't receive the spa therapy immediately.HADS is a self-administered scale of 14 items, divided into 2 subscales of 7 items (Anxiety or HADS-A, Depression or HADS-D). It contains no somatic item that can be confused with symptomatic manifestations of a disease. Each item is scored on a scale of 0 to 3. A score is generated for each of the two sub-scales and for the entire HADS (HADS-T). Limit scores distinguish between: non-cases or asymptomatic cases (score ≤ 7); probable or borderline cases (score 8-10); clearly or clinically symptomatic cases (score ≥ 11).

Central Contacts

Isabelle LAFFONT

CONTACT

04 67 33 23 46 i-laffont@chu-montpellier.fr

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.